Prospective evaluation of QTc-interval prolongation in patients with advanced ovarian cancer after treatment with carboplatin, paclitaxel and bevacizumab
J Puppe, D van Ooyen, J Neise, F Thangarajah, C Eichler, C Fridrich, B Morgenstern, R Pfister, P Mallmann, M Wirtz, G Michels · Geburtshilfe und Frauenheilkunde · 2016 · Heft 10
Bibliografische Angaben
Zusammenfassung
Background: Angiogenesis has become an important target for antineoplastic therapy of advanced ovarian cancer and the monoclonal antibody bevacizumab directed against the vascular endothelial growth factor (VEGF) is broadly used in the clinic. This drug is associated with cardiovacular toxicities such as hypertension. However, the effect of bevacizumab on life-threatening electrocardiographic alterations including corrected QT (QTc) interval prolongation remains unclear. Patients and methods: In this feasibility study we assessed the effect of carboplatin (AUC 6), paclitaxel (175 mg/m2), and bevacizumab (15 mg/k…
